The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Open accessAbstract
A MESSAGE FROM ASCO'S PRESIDENT: Nearly 40 years ago, President Richard Nixon signed the National Cancer Act, mobilizing the country's resources to make the “conquest of cancer a national crusade.” That declaration led to a major investment in cancer research that has significantly improved cancer prevention, treatment, and survival. As a result, two thirds of people diagnosed with cancer today will live at least 5 years after diagnosis, compared with just half in the 1970s. In addition, there are now more than 12 million cancer survivors in the United States—up from 3 million in 1971. Scientifically, we have never been in a better position to advance cancer treatment. Basic scientific research, fueled in recent years by the tools of molecular biology, has generated unprecedented knowledge of cancer development. We now understand many of the cellular pathways that can lead to cancer. We have learned how to develop drugs that block those pathways; increasingly, we know how to personalize therapy to the unique genetics of the tumor and the patient. Yet in 2008, 1.4 million people in the United States will still be diagnosed with cancer, and more than half a million will die as a result of the disease. Some cancers remain stubbornly resistant to treatment, whereas others cannot be detected until they are in their advanced, less curable stages. Biologically, the cancer cell is notoriously wily; each time we throw an obstacle in its path, it finds an alternate route that must then be blocked. To translate our growing basic science knowledge into better treatments for patients, a new national commitment to cancer research is urgently needed. However, funding for cancer research has stagnated. The budgets of the National Institutes of Health and the National Cancer Institute have failed to keep pace with inflation, declining up to 13% in real terms since 2004. Tighter budgets reduce incentives to support high-risk research that could have the largest payoffs. The most significant clinical research is conducted increasingly overseas. In addition, talented young physicians in the United States, seeing less opportunity in the field of oncology, are choosing other specialties instead. Although greater investment in research is critical, the need for new therapies is only part of the challenge. Far too many people in the United States lack access to the treatments that already exist, leading to unnecessary suffering and death. Uninsured cancer patients are significantly more likely to die than those with insurance, racial disparities in cancer incidence and mortality remain stark, and even insured patients struggle to keep up with the rapidly rising cost of cancer therapies. As this annual American Society of Clinical Oncology report of the major cancer research advances during the last year demonstrates, we are making important progress against cancer. But sound public policies are essential to accelerate that progress. In 2009, we have an opportunity to reinvest in cancer research, and to support policies that will help ensure that every individual in the United States receives potentially life-saving cancer prevention, early detection, and treatment. Sincerely, Richard L. Schilsky, MD President American Society of Clinical Oncology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Self-citationWright, A. A. (2008) · JAMA · doi:10.1001/jama.300.14.1665 · Cited by 2,788
Lippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., Parnes, H. L., Minasian, L. M., Gaziano, J. M., Hartline, J. A., et al. (2009) · JAMA · doi:10.1001/jama.2008.864 · Cited by 2,122
Self-citationDetection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Chaturvedi, A. K., Engels, E. A., Anderson, W. F., & Gillison, M. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1713 · Cited by 1,567
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Vestergaard, M. E., Macaskill, P., Holt, P. E., & Menzies, S. W. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08713.x · Cited by 862
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) · The Lancet · doi:10.1016/s0140-6736(08)60167-1 · Cited by 822
Increasing Burden of Melanoma in the United States
Linos, E., Swetter, S. M., Cockburn, M. G., Colditz, G. A., & Clarke, C. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.423 · Cited by 746
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Pointreau, Y., Garaud, P., Chapet, S., Sire, C., Tuchais, C., Tortochaux, J., Faivre, S., Guerrif, S., Alfonsi, M., & Calais, G. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp007 · Cited by 577
Smith, R. A., Cokkinides, V., & Brawley, O. W. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20008 · Cited by 495
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Self-citationMotesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
Phelps, A. C. (2009) · JAMA · doi:10.1001/jama.2009.341 · Cited by 462
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
Janot, F., de Raucourt, D., Benhamou, E., Ferron, C., Dolivet, G., Bensadoun, R.-J., Hamoir, M., Géry, B., Julieron, M., Castaing, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0102 · Cited by 405
Evaluation of Trends in the Cost of Initial Cancer Treatment
Warren, J. L., Yabroff, K. R., Meekins, A., Topor, M., Lamont, E. B., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn175 · Cited by 388
Van Cutsem, E., Lang, I., D'haens, G., Moiseyenko, V., Zaluski, J., Folprecht, G., Tejpar, S., Kisker, O., Stroh, C., & Rougier, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2 · Cited by 372
Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., Batzel, G. N., Yin, D., Pritchard-Jones, K., Judson, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70354-7 · Cited by 340
Settle, K., Posner, M. R., Schumaker, L. M., Tan, M., Suntharalingam, M., Goloubeva, O., Strome, S. E., Haddad, R. I., Patel, S. S., Cambell, E. V., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0149 · Cited by 296
Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial
Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F., Tangen, C. M., Parnes, H. L., Lippman, S. M., La Rosa, F. G., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm117 · Cited by 266
McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., Richards, J., Jakub, J. W., Beeram, M., Tarantolo, S., Agarwala, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8288 · Cited by 250
Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9000 · Cited by 229
Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 213
Kwak, E. L., Camidge, D. R., Clark, J., Shapiro, G. I., Maki, R. G., Ratain, M. J., Solomon, B., Bang, Y., Ou, S., & Salgia, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3509 · Cited by 207
Neuhouser, M. L., Wassertheil-Smoller, S., Thomson, C., Aragaki, A., Anderson, G. L., Manson, J. E., Patterson, R. E., Rohan, T. E., van Horn, L., Shikany, J. M., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.540 · Cited by 204
Goss, P. E., Ingle, J. N., Pater, J. L., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6798 · Cited by 191
Acupuncture for Pain and Dysfunction After Neck Dissection: Results of a Randomized Controlled Trial
Pfister, D. G., Cassileth, B. R., Deng, G. E., Yeung, K. S., Lee, J. S., Garrity, D., Cronin, A., Lee, N., Kraus, D., Shaha, A. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9860 · Cited by 184
Self-citationPirker, R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., Gatzemeier, U., Bajeta, E., Emig, M., & Pereira, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3 · Cited by 172
Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening
Croswell, J. M., Kramer, B. S., Kreimer, A. R., Prorok, P. C., Xu, J.-L., Baker, S. G., Fagerstrom, R. M., Riley, T. L., Clapp, J. D., Berg, C. D., et al. (2009) · The Annals of Family Medicine · doi:10.1370/afm.942 · Cited by 167
Self-citationLoehrer, P. J., Powell, M. E., Cardenes, H. R., Wagner, L. I., Brell, J. M., Ramanathan, R., Crane, C. H., Alberts, S. R., & Benson, A. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4506 · Cited by 153
Self-citationMuss, H. B., Tu, D., Ingle, J. N., Martino, S., Robert, N. J., Pater, J. L., Whelan, T. J., Palmer, M., Piccart, M. J., Shepherd, L. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6334 · Cited by 151
Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K. A., Zheng, M., Dimery, I. W., & Friedman, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2010b · Cited by 144
Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson, K. M., Daifotis, A. G., & Gann, P. H. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm130 · Cited by 132
Kramer, B. S., Hagerty, K. L., Justman, S., Somerfield, M. R., Albertsen, P. C., Blot, W. J., Carter, H. B., Costantino, J. P., Epstein, J. I., Godley, P. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9599 · Cited by 123
Self-citationHershman, D. L., Unger, J. M., Barlow, W. E., Hutchins, L. F., Martino, S., Osborne, C. K., Livingston, R. B., & Albain, K. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1163 · Cited by 119
Pirker, R., Ramlau, R., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., & Vansteenkiste, J. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0748 · Cited by 114
Dawood, S. S., Broglio, K. R., Kau, S., Green, M. C., Giordano, S. H., Meric‐Bernstam, F., Buchholz, T. A., Albarracin, C. T., Yang, W. T., Hennessy, B. T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9952 · Cited by 112
Am, E., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Gore, M. E., MacKie, R., et al. (2008) · Research Explorer (The University of Manchester) · Cited by 111
Re: Mortality Results from a Randomized Prostate-Cancer Screening Trial
Roobol, M. J. (2009) · European Urology · doi:10.1016/j.eururo.2009.03.085 · Cited by 100
Current and Future Utilization of Services From Medical Oncologists
Warren, J. L., Mariotto, A. B., Meekins, A., Topor, M. A., & Brown, M. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6357 · Cited by 92
Sargent, D. J., Marsoni, S., Thibodeau, S. N., Labianca, R., Hamilton, S. R., Torri, V., Monges, G., Ribic, C. M., Grothey, A. A., & Gallinger, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4008 · Cited by 91
Belani, C. P., Brodowicz, T., Ciuleanu, T.-E., Kim, J. H., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Krejcy, K., & Zielinski, C. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra8000 · Cited by 83
Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?
Sargent, D. J., & Hayes, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8064 · Cited by 80
Cardenes, H. R., Moore, A. M., Johnson, C. S., Yu, M., Helft, P. R., Chiorean, E. G., Vinson, J., Howard, T. J., Stephens, A. W., Tai, D. F., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181e9c103 · Cited by 77
Self-citationKumar, K., Brim, H., Giardiello, F. M., Smoot, D. T., Nouraie, M. S., Lee, E. L., & Ashktorab, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1029 · Cited by 73
Gray, R. G., Rea, D. W., Handley, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.513 · Cited by 69
Cancer Screening before and after Switching to a High-Deductible Health Plan
Wharam, J. F., Galbraith, A. A., Kleinman, K., Soumerai, S. B., Ross‐Degnan, D., & Landon, B. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00004 · Cited by 69
Refractory Thyroid Cancer: A Paradigm Shift in Treatment Is Not Far Off
Pfister, D. G., & Fagin, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3682 · Cited by 62
Self-citationHayanga, A. J. (2009) · Archives of Surgery · doi:10.1001/archsurg.2009.68 · Cited by 57
Ryan, J. L., Heckler, C. E., Dakhil, S. R., Kirshner, J. J., Flynn, P. J., Hickok, J. T., & Morrow, G. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9511 · Cited by 53
Pető, R., & Davies, C. M. (2008) · Breast Cancer Research and Treatment · Cited by 48
Olmos, D., Okuno, S., Schuetze, S. M., Paccagnella, M. L., Yin, D., Gualberto, A., Worden, F. P., Haluska, P., Bono, J. S. D., & Scurr, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.10501 · Cited by 42
29th Annual San Antonio Breast Cancer Symposium 2006
(2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9567-y · Cited by 31
Miles, B. J., & Eigl, B. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5077 · Cited by 28
Nathan, P. C., Ness, K. K., Hudson, M. M., Mahoney, M. C., Ford, J. S., Landier, W., Armstrong, G., Henderson, T. O., Robison, L. L., & Oeffinger, K. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra6501 · Cited by 4
Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM
Sampson, J. H., Archer, G. E., Bigner, D. D., Schmittling, R. J., Herndon, J. E., Davis, T. A., Friedman, H. S., Keler, T., Reardon, D. A., & Mitchell, D. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2034 · Cited by 2
Cited by
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
Metadata
- Authors
- Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., Markman, M., Mayer, R., Pfister, D., Raghavan, D., Ramsey, S., Reaman, G., Sandler, H., Sawaya, R., Schuchter, L., Sweetenham, J., Vahdat, L., & Schilsky, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 812-826
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169436143
- Cited by
- 293
- References
- 64
- FWCI
- 47.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.